AbbVie Inc (ABBV)vsNewGenIvf Group Limited Class A Ordinary Shares (NIVF)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
NIVF
NewGenIvf Group Limited Class A Ordinary Shares
$1.72
-6.01%
HEALTHCARE · Cap: $1.11M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1293908% more annual revenue ($61.16B vs $4.73M). NIVF leads profitability with a 209.0% profit margin vs 6.9%. NIVF trades at a lower P/E of 0.1x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
NIVF
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Intrinsic value data unavailable for NIVF.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 79 in profit
Keeps 209 of every $100 in revenue as profit
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of -349.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : NIVF
The strongest argument for NIVF centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 209.0% and operating margin at -349.1%. Revenue growth of 11.9% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : NIVF
The primary concerns for NIVF are EPS Growth, Market Cap, Operating Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while NIVF is a mature play — different risk/reward profiles.
ABBV carries more volatility with a beta of 0.36 — expect wider price swings.
NIVF is growing revenue faster at 11.9% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 57/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
NewGenIvf Group Limited Class A Ordinary Shares
HEALTHCARE · MEDICAL CARE FACILITIES · USA
NewGenIvf Group Limited (NIVF) is a leading entity in the reproductive health industry, focusing on cutting-edge fertility solutions and sophisticated in vitro fertilization (IVF) services. With a commitment to increasing success rates in assisted reproductive techniques, NIVF is strategically positioned to meet the rising global demand for fertility treatments through an established clinic network and key partnerships. As the market for fertility services continues to expand, the company is poised for significant growth, reinforcing its dedication to helping individuals and couples achieve their aspirations of parenthood.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?